title: 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer.
abstract: OBJECTIVE
  Our aim was to evaluate in anaplastic thyroid carcinoma (ATC) patients the value of 18F-FDG PET/CT compared with total body computed tomography (CT) using intravenous contrast material for initial staging, prognostic assessment, therapeutic monitoring and follow-up.
  
  
  METHODS
  Twenty consecutive ATC patients underwent PET/CT for initial staging. PET/CT was performed again during follow-up. The gold standard was progression on imaging follow-up (CT or PET/CT) or confirmation with another imaging modality.
  
  
  RESULTS
  A total of 265 lesions in 63 organs were depicted in 18 patients. Thirty-five per cent of involved organs were demonstrated only with PET/CT and one involved organ only with CT. In three patients, the extent of disease was significantly changed with PET/CT that demonstrated unknown metastases. Initial treatment modalities were modified by PET/CT findings in 25% of cases. The volume of FDG uptake (≥300 ml) and the intensity of FDG uptake (SUVmax≥18) were significant prognostic factors for survival. PET/CT permitted an earlier assessment of tumour response to treatment than CT in 4 of the 11 patients in whom both examinations were performed. After treatment with combined radiotherapy and chemotherapy, only the two patients with a negative control PET/CT had a confirmed complete remission at 14 and 38 months; all eight patients who had persistent FDG uptake during treatment had a clinical recurrence and died.
  
  
  CONCLUSIONS
  FDG PET/CT appears to be the reference imaging modality for ATC at initial staging and seems promising in the early evaluation of treatment response and follow-up.
authors.affiliation: Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy and University Paris-Sud XI, 94805, Villejuif Cedex, France. poisson.t@gmail.com
authors.forename: Thomas
authors.initials: T
authors.lastname: Poisson
authors.forename: Désirée
authors.initials: D
authors.lastname: Deandreis
authors.forename: Sophie
authors.initials: S
authors.lastname: Leboulleux
authors.forename: François
authors.initials: F
authors.lastname: Bidault
authors.forename: Guillaume
authors.initials: G
authors.lastname: Bonniaud
authors.forename: Sylvain
authors.initials: S
authors.lastname: Baillot
authors.forename: Anne
authors.initials: A
authors.lastname: Aupérin
authors.forename: Abir
authors.initials: A
authors.lastname: Al Ghuzlan
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Travagli
authors.forename: Jean
authors.initials: J
authors.lastname: Lumbroso
authors.forename: Eric
authors.initials: E
authors.lastname: Baudin
authors.forename: Martin
authors.initials: M
authors.lastname: Schlumberger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D065646:Thyroid Carcinoma, Anaplastic; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed / Q000379:methods*; D051598:Whole Body Imaging / Q000379:methods*
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18